Arrowhead Pharmaceuticals vs Chemed

Arrowhead Pharmaceuticals (ARWR), health care, and Chemed (CHE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Chemed is worth $7.1B on the stock market and Arrowhead Pharmaceuticals $6.1B: Chemed is valued at 17% more. Arrowhead Pharmaceuticals's operating margin in its latest fiscal year was 11.9% and Chemed's 13.4%. Over the past year Arrowhead Pharmaceuticals's share price has moved +9.24% and Chemed's +26.2%.

Key facts

Arrowhead Pharmaceuticals market value
$6.1B
Chemed market value
$7.1B
Chemed P/E
26.2
Arrowhead Pharmaceuticals revenue
$829.4MFY to 2025-09-30
Chemed revenue
$2.5BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Arrowhead Pharmaceuticals vs Chemed: every measure side by side
Measure Arrowhead Pharmaceuticals Chemed
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-09-302025-12-31
Size
Market cap$6.1Blower$7.1Bhigher
Revenue$829.4Mlower$2.5Bhigher
Earnings-$1.6Mlower$265.2Mhigher
Employees711lower15,811higher
Total assets$1.4Blower$1.5Bhigher
Valuation
P/E—26.2
P/S7.3higher2.8lower
P/B121higher8.2lower
Dividend yield0.00%lower0.46%higher
Profitability
Operating margin11.9%lower13.4%higher
Balance sheet
Net assets$466.1Mlower$979.4Mhigher
Total liabilities$881.9Mhigher$558.8Mlower
Total debt——
Cash on hand$226.5Mhigher$74.5Mlower
Price change
Today-2.76%lower-0.49%higher
1 year+9.24%lower+26.2%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Arrowhead Pharmaceuticals only (2)

Chemed only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns ARWR · Who owns CHE

Further comparisons

Learn

Questions and answers

Which is bigger, Arrowhead Pharmaceuticals or Chemed?

By market value, Chemed is the larger: $7.1B against $6.1B for Arrowhead Pharmaceuticals. By revenue in its latest fiscal year, Chemed is the larger: $2.5B against $829.4M for Arrowhead Pharmaceuticals.

Which has the higher operating margin?

Chemed: 13.4%, against 11.9% for Arrowhead Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Chemed: 0.46%, against 0.00% for Arrowhead Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Arrowhead Pharmaceuticals and Chemed?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Arrowhead Pharmaceuticals and 0 hold Chemed.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals vs Chemed”, data as of 17 November 2026. https://funkfolio.com/compare/arwr-vs-che

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.